SAMPLE ALERTS
View sample alerts with expert analyses from the inThought team.
Keytruda/Inlyta combo granted accelerated approval by FDA for 1L advanced RCC
April 25, 2019 Impact level: High According to an updated label, FDA has granted accelerated approval to use of Keytruda (pembrolizumab; PD-1) in combination with Inlyta (axitinib; TKI) in 1L renal cell carcinoma (RCC). inThought…
Novartis remains in BCMA CAR-T space through Poseida investment after discontinuing in-house program
April 22, 2019 Impact Level: High Novartis has contributed $75 million towards a Series C financing for CAR-T company Poseida, which totaled $142 million from current and new investors. Poseida has two BCMA CAR-Ts: dosing in…
